 |
|
|
 |
|
LEADERS IN METASTATIC BREAST CANCER CHEMOTHERAPYSpecialised Therapeutics Pty Ltd (STA) is a privately held, non listed Australian company dedicated to helping Australians fight serious diseases such as stage four breast cancer, pancreatic cancer, lung cancer and melanoma. Founded in 2007, STA’s mission is to in-license and develop unique and specialised drug technologies which deliver superior patient benefits. Our current focus is in cancer, both the treatment and amelioration of side effects associated with many cancer therapies through two world leading therapies ABRAXANE® (nanoparticle albumin-bound paclitaxel) and ALOXI® (palonosetron HCL) respectively. To read more about these therapies, please click on the product name on this page. Treatments For Breast CancerAccording to Cancer Australia, breast cancer is the most common cancer among Australian women, with over 12,500 new cases diagnosed per annum which accounts for 27% of all cancer diagnoses in 2007.1 Advances in breast cancer treatment have seen an increase in breast cancer survival. Between the periods of 1982-1987 and 2000-2006, five-year relative survival increased from 72.6% to 88.3% respectively.2 Advances in treatment regimens including chemotherapy for breast cancer, combined with early detection has been largely responsible for the positive trend in breast cancer survival statistics. Specialised Therapeutics Australia continues to work in the field of breast cancer, with ABRAXANE chemotherapy as a leading treatment for metastatic (stage 4) breast cancer. References: |
LATEST NEWS, EVENTS AND MEDIAGliolan® Granted Orphan Drug Status by the Therapeutic Goods AdministrationA drug which aids neurosurgeons to better visualise and more completely remove malignant brain tumours has been granted orphan drug status by the Therapeutic Goods Administration (TGA).First Australian Patients Treated With New Brain Tumour Drug - Gliolan®Melbourne, Australia: Two Australian patients have undergone surgery with the aid of a new drug which assists neurosurgeons to visualise and remove high grade gliomas - brain tumours which typically have a poor prognosis. Neurosurgeons at Brisbane’s Wesley Hospital and the Royal Melbourne Hospital have pioneered the use of Gliolan® (5-aminolevulinic acid), describing it as “breakthrough technology”.Specialised Therapeutics Australia Extends Collaboration with Swiss Helsinn GroupMelbourne bio-pharmaceutical company Specialised Therapeutics Australia plans to further expand its oncology portfolio, to include a new product for the prevention of chemotherapy-induced nausea and vomiting.Specialised Therapeutics to License Brain Tumour Visualisation Drug Gliolan® in Australia & NZA new drug which aids neurosurgeons to better visualise and operate on brain tumours that have a poor prognosis, high grade gliomas, will be available in Australia under a special access program later this year.World leading breast cancer drug now available in New ZealandNew Zealand women now have access to a leading breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer after failure of anthracycline therapy.Specialised Therapeutics and Helsinn Group announce a PBS Listing for Aloxi® (Palonosetron) in AustraliaLeading anti-nausea/anti-vomiting drug available November 1st. PBS listed for Australian cancer patients.Celgene acquires Abraxis BioScience and leading anti-cancer drug AbraxaneIn Australia and New Zealand, Celgene assumes partnership role with Specialised Therapeutics Australia (STA). STA to continue as the exclusive distributor of Abraxane in Australia and New Zealand.Specialised Therapeutics’ Compassionate Program has provided cancer patients access to over $1m of cancer drug, ABRAXANE® since TGA approvalHundreds of cancer patients around Australia have had free and subsidised access to a world leading cancer drug, under a compassionate program administered by the family-owned bio-pharmaceutical company which markets the treatment in Australia.Approval granted to market ABRAXANE® in New ZealandMEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority, has approved for marketing ABRAXANE® for the treatment of metastatic breast cancer.PBS change for leading breast cancer drug ABRAXANE®From 1 July, Abraxane will be available via PBS Authority to patients with ‘Metastatic breast cancer after failure of prior therapy.’ |
|
|